. 2017 Sep 25;6(8):R171–R181. doi: 10.1530/EC-17-0203
This work is licensed under a Figure 1.
TransCon GH is a sustained-release inactive prodrug consisting of parent drug, unmodified GH, transiently bound to a carrier, mPEG (40 kDa), via a proprietary TransCon linker that is autohydrolyzed under physiologic pH and temperature. Reproduced under the terms of the original CCBY licence, from Chatelain P, Malievskiy O, Radziuk K, Senatorova G, Abdou MO, Vlachopapadopoulou E, Skorodok Y, Peterkova V, Leff JA, Beckert M, et al. A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency, Journal of Clinical Endocrinology and Metabolism, 2017, volume 102, pages 1673–1682, (doi:10.1210/jc.2016-3776).